More drugs in development are failing to make it to market, according to Acting FDA Commissioner Lester M. Crawford. Historically, 14% of drugs entering Phase I have won approval, Crawford said in a speech to the Banc of America Securities Healthcare Institutional Conference on July 7, but now only 8% reach the marketplace. One-half fail in Phase III, he added, compared to one in five in the past. This has pushed the cost of developing a drug from $1.1 billion in 1995 to $1.7 billion in 2002, he says.

The reason why more drugs are falling by the wayside isn't clear, according to Sandra Kweder, deputy director of the FDA's Office of New Drugs. "It might be a business decision," she says. "The drug may work, but the company decides that it might not work well enough or in just the right way to give them the market share that...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?